Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of Options

12 Jul 2010 07:00

RNS Number : 1751P
ViaLogy PLC
12 July 2010
 



VIALOGY PLC

GRANT OF OPTIONS

Pasadena, July 12, 2010. ViaLogy PLC (LSE: VIY). On the recommendation of its remuneration committee, ViaLogy PLC announces the approval of new three-year employment contracts for the company's senior management and executive directors. The contracts include performance criteria and ensure management continuity for a critical period of the ViaLogy's development. The contracts also include the following time-based share option incentive awards:

Director
Options
Price
Exercise period
 
 
 
 
Terry Bond, Chairman
4,475,408
3.75p
From 22nd June 2013 for 7 years
Terry Bond, Chairman
4,475,408
1p
From 22nd June 2013 for 7 years
Dr Robert Dean, CEO
3,032,421
3.75p
From 22nd June 2012 for 8 years 
Dr Robert Dean, CEO
3,032,422
1p
From 22nd June 2012 for 8 years 
Dr Sandeep Gulati, CTO
8,376,459
1p
Immediately for a period of 10 years 

Concurrent with these option grants, the Board has directed the executive management team to extend the application of its core technologies to additional oil patch product and service markets to include hydraulic fracturing and production operations, and shale gas plays, to generate future revenues and to realize greater value from core technology assets in upstream energy markets. The company's work to bring its QuantumRD technology from its current application as an internal platform to a licensable product for other companies is already underway.

In addition the company has granted a further 10,599,331 options to senior management, 5,299,665 have been granted at 3.75p, the remaining 5,299,666 options being granted at 1p per share. All of these options are fully exercisable from 2 July 2013 for seven years. Further information from: Robert W Dean, President & CEO - US +1 626-296-6337 Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 Nominated Advisor to ViaLogy PLC (Seymour Pierce) Mark Percy / Catherine Leftley, Corporate Finance +44 (0) 20-7107-8000 Katie Ratner / Jeremy Stephenson, Corporate Broking +44 (0) 20-7107-8000

About ViaLogy: ViaLogy provides reservoir characterization, geophysical imaging and hydrocarbon sizing services to global oil and gas customers based on proprietary, patented active signal processing technology. ViaLogy's QuantumRD platform assists clients in de-risking prospects over a broad range of subsurface lithologies and complex stratigraphies to generate drilling targets, position offsets and enhance recovery. ViaLogy's core technology rapidly and accurately detects weak signals buried in high noise background and clutter, and is applicable to active/passive seismic, electromagnetic and magnetotelluric data. By exploiting normally disregarded noise variations induced by changes in porosity, fluid presence and permeability across the formation, and adding computer-designed noise to the data, ViaLogy is able to amplify subtle noise variations to enhance areal and depth resolution in complex lithologies that are not achievable through conventional means. For more information on ViaLogy, visit www.vialogy.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCDMGMNZMVGGZZ
Date   Source Headline
6th Apr 20204:40 pmRNSSecond Price Monitoring Extn
6th Apr 20204:36 pmRNSPrice Monitoring Extension
27th Mar 20203:00 pmRNSIssue of Share Options
25th Mar 20207:00 amRNSContract manufacturing agreement for COVID-19 test
16th Mar 20204:41 pmRNSSecond Price Monitoring Extn
16th Mar 20204:36 pmRNSPrice Monitoring Extension
13th Mar 202011:51 amRNSHolding(s) in Company
10th Mar 20207:00 amRNSAcquisition of French distribution channel
17th Feb 20207:00 amRNSCE Marking Technical File submission
14th Feb 202011:00 amRNSMedilink Award win for Outstanding Achievement
14th Feb 20207:00 amRNSTGA approves DPYD for sale in Australia
5th Dec 201912:10 pmRNSThe Healthcare+ Expo Taiwan
2nd Dec 20197:00 amRNSHalf-year Report
29th Nov 201912:05 pmRNSBionow Double Award Win
28th Nov 20197:00 amRNSOpening of New Facilities and Corporate HQ
15th Nov 20197:00 amRNSPrivate Investor Presentation
12th Nov 201910:12 amRNSNotice of Results
6th Nov 20191:52 pmRNSCapital Markets Day
1st Nov 20197:00 amRNSDirector/PDMR Shareholding
31st Oct 20197:00 amRNSLaunch of Yourgene FlexT Analysis Software
30th Oct 20197:00 amRNSIssue of Share Options
15th Oct 20197:00 amRNSAmerican Society of Human Genetics Annual Meeting
14th Oct 20197:00 amRNSHalf year trading update
1st Oct 20197:00 amRNSPrivate Investor Presentation
26th Sep 20197:00 amRNSCE-IVD Certification renewal
18th Sep 20197:00 amRNSLaunch of DPYD chemotoxicity diagnostic assay
17th Sep 20195:50 pmRNSResult of AGM
17th Sep 20197:00 amRNSAGM Statement
20th Aug 20197:00 amRNSNotice of AGM
19th Aug 201910:35 amRNSChange of Registered Office
16th Aug 20193:49 pmRNSHolding(s) in Company
16th Aug 20199:06 amRNSDirectorate Change
12th Aug 20197:00 amRNSAmendment to Share Options
1st Aug 20197:00 amRNSDirector/PDMR Shareholding
29th Jul 20197:00 amRNSAppointment of Director
10th Jul 20197:00 amRNSFinal Results, Business Update and Director Change
27th Jun 20197:00 amRNSNotice of Results
24th Jun 20197:00 amRNSYourgene participates in key global conferences
3rd Jun 20197:01 amRNSDirector's dealing
3rd Jun 20197:00 amRNSIssue of Share Options
9th May 20194:07 pmRNSDirector's dealing
9th May 20197:00 amRNSDirectors' dealing & warrant extension
1st May 20198:05 amRNSTotal Voting Rights
26th Apr 20195:12 pmRNSHolding(s) in Company
26th Apr 20195:01 pmRNSHolding(s) in Company
25th Apr 20194:40 pmRNSCompletion of Acquisition
18th Apr 20197:00 amRNSResults of Placing and Subscription
17th Apr 20194:50 pmRNSAppointment of Sole Corporate Broker
17th Apr 20194:48 pmRNSProposed Acquisition, Placing & Subscription
8th Apr 20197:00 amRNSFull-year Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.